Thus, pharmacological treatment of CE may protect nigrostriatal neurons from MPTP-mediated toxicity and may pave a new pathway for BDNF, FGF2 and TrkB/Akt signaling axis as targets for the treatment of PD. The gene discussed is FGF2; the disease is Parkinson disease.